Hamid Elia Daaboul, MD, PhD is an ASCO active member and researcher in the mode of action of new potential anticancer molecules in the Lebanese American University, Lebanon. He is a practicing Oncologist and also a former head of department of Oncology in Haroun Hospital, Lebanon. He earned his PhD in Oncology from Surrey University, London. He studied the mode of action of β-2-himachalen-6-ol, a new anticancer molecule, and succeeded in identifying its apoptotic effect via the inhibition of the mitogen-activated protein kinases (MAPK/ERK) and the phosphatidylinositol 3-kinase (PI3K/AKT) cellular signalling pathways. He is also engaged in clinical trials of other potentially active anticancer molecules.